COMBINATION TREATMENT WITH NOVEL BCL2 INHIBITOR SONROTOCLAX (BGB‐11417) + ZANUBRUTINIB INDUCES HIGH RATE OF COMPLETE REMISSION IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA | Publicación